A cross-over study compares oral liposomal iron and iron polymaltose in children with CKD iron deficiency anemia, suggesting differing efficacy and tolerability.
Key Points
This study aims to compare the effectiveness and tolerability of liposomal iron and iron polymaltose in children with chronic kidney disease and iron deficiency anemia.
Conducted a cross-over study with 33 children having CKD and iron deficiency anemia.
Participants received either liposomal iron or iron polymaltose for 3 months, followed by an 8-week washout before switching therapies.
Measured hemoglobin, iron indices, bone minerals, and 25(OH)D at different intervals.
Approximately 48% of participants showed an increase in hemoglobin levels after liposomal iron, while 51.5% did after iron polymaltose.
No significant difference in hemoglobin or iron indices between the two therapies was found (p > 0.05).
Iron polymaltose showed greater hemoglobin increase and better transferrin saturation results than liposomal iron.
Iron polymaltose led to a notable decrease in serum phosphorus.